DrugIn clinical trials
Мебуфотенин (5-MeO-DMT, BPL-003)
mebufotenin
Назальный мебуфотенина бензоат исследуется при резистентной депрессии; фаза 2b (193 взрослых, JAMA 2026) показала снижение MADRS к 29-му дню против малой дозы сравнения. Не одобрен.
Also in the catalogue
- Yang Y, et al. SGLT2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: Meta-Analysis of RCTs. JAMA, 2026Publication
- Vacheron CH, et al. Influence of Preoperative Virtual Reality on Preoperative State Anxiety in the Ambulatory Setting: The AMBLUMEEN RCT. Anesth Analg, 2026Publication
- ЛорундростатDrug
- Feifel D, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression. JAMA, 2026Publication
- UpacicalcetDrug
- DivarasibDrug
Scales
Identifiers
- INN
- mebufotenin
- Code
- BPL-003
Details
- Status
- In clinical trials
- Class
- агонист серотониновых рецепторов 5-HT1A и 5-HT2A, короткодействующий психоделик
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.